Table 1 Vimentin protein expression in curettage samples is associated with clinicopathological variables in endometrial cancer patients.

From: Loss of vimentin expression in preoperative biopsies independently predicts poor prognosis, lymph node metastasis and recurrence in endometrial cancer

Variable

Vim pos n (%)

Vim loss n (%)

P-value

Number of patients

1364

119

 

Age

  

<0.001

<66

666 (95)

37 (5)

 

≥66

698 (89)

82 (11)

 

FIGO-09 stagea

  

<0.001

I–II

1147 (93)

83 (7)

 

III–IV

212 (86)

35 (14)

 

Histologic typea

  

<0.001

Endometrioid

1134 (95)

66 (5)

 

Serous

122 (82)

26 (18)

 

Clear cell

41 (73)

15 (27)

 

Carcinosarcoma

46 (85)

8 (15)

 

Undifferentiated

19 (83)

4 (17)

 

Histologic gradea,b

  

0.529

Grade 1

535 (95)

26 (5)

 

Grade 2

422 (93)

32 (7)

 

Grade 3

165 (95)

8 (5)

 

Myometrial infiltrationa

  

<0.001

<50%

806 (95)

43 (5)

 

≥50%

452 (88)

60 (12)

 

Recurrencea,c

  

<0.001

No

1063 (94)

67 (6)

 

Yes

214 (86)

35 (14)

 

Lymph node metastasisa

  

0.001

No

818 (93)

64 (7)

 

Yes

120 (84)

22 (16)

 
  1. FIGO International Federation of Gynaecologist and Obstetrics, n number of patients, Vim pos positive vimentin expression, Vim loss loss of vimentin expression.
  2. Positive: SI 1–9, Loss: SI 0.
  3. Statistically significant P-values (<0.05) are bold.
  4. aData missing on FIGO stage for 6 patients, histologic type for 1 patient, myometrial infiltration for 122 patients, and lymph node metastatic status for 459 patients.
  5. bEndometrioid histology only.
  6. c104 patients with metastasis at primary treatment are censored.
Back to article page